Ponesimod (ACT-128800) is an orally active sphingosine-1-phosphate (S1P) receptor modulator [1
] that was developed as a disease-modifying therapy (DMT) for multiple sclerosis (MS). The compound is reported as a partial S1P4
receptor agonist, with maximum activity 18% and 42% of that induced by the endogenous ligand S1P (at 10μM ACT-128800) [1
The INN record for ponesimod stipulates the (2R)
receptor agonists are being developed and investigated for immunomodulatory/immunosuppressant potential in autoimmune diseases.